Artificial Intelligence

Syntiant unveils ultra-thin AI chips for hearables and smart remotes, aiming to dominate the booming market for miniaturized intelligent devices.

SoftBank is buying digital infrastructure giant DigitalBridge for $4B, a bold move to own the data centers and fiber needed to power its AI ambitions.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

A chiropractor with millions of followers claims he can reverse dementia. As science eyes a breakthrough, we examine the hope, the hype, and the business.

Professional Diversity Network invests millions in an AI crypto token, a risky move signaling a dramatic pivot into the volatile world of Web3 finance.

A new AI assistant is being piloted in the UAE, promising to cut doctor paperwork by 50% and give patients more face-to-face attention.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

The investment firm sheds its medical focus, adopting a new name and a broader mandate to chase cross-sector opportunities in the booming AI market.

A pivotal trial for an acute myeloid leukemia drug is delayed for a promising reason: patients are surviving longer than anticipated, fueling cautious optimism.

The InsurTech firm is shedding non-core units to slash debt by over 50% and double down on its AI platforms, RELI Exchange and 5minuteinsure.com.

Israeli innovator Foresight gets a major nod from Audi, showcasing its all-weather 3D vision system that could redefine autonomous vehicle safety.

Cleveland expands its AI security robot program, citing reduced crime. But as other cities watch, questions of cost, privacy, and effectiveness emerge.

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

After a 600%+ stock surge and an abrupt SEC trading halt, Charming Medical is now facing class action lawsuits alleging a social media manipulation scheme.

iQSTEL caps a transformational year with a NASDAQ uplist, record revenue, and a strategic pivot to Fintech and Cybersecurity, eyeing a $1B future.

A Korean AI startup raised $854K for a gesture-control ring, betting its enterprise-grade tech can unlock the future of post-touch computing.

Early data shows QurAlis' QRL-101 successfully engaged its intended target in ALS patients, a key step for a novel drug aimed at quelling neuronal storm.

Gogo has launched its anticipated 5G network for business jets, promising a new era of speed. But can its regional advantage hold against global satellite rivals?

Traini's new generative AI collar claims to translate dog emotions into human language. But does the science back up this multi-million dollar bet?